Tianhong “Tina” Li, MD, PhD
2018 - 2020
Dr. Tianhong “Tina” Li is a medical oncologist in the Department of Internal Medicine, Division of Hematology/Oncology at the University of California at Davis (UC Davis). Currently, she serves as co-director of the Phase I program and co-leader of the breast cancer research program at UC Davis Comprehensive Cancer Center. She has clinical and laboratory expertise in lung and breast cancer research. She also serves as UC Davis site co-Principal Investigator for the UC-wide ATHENA breast health multi-campus research initiative. She is an active member of California Cancer Consortium and Southwest Oncology Group (SWOG), and serves in the Membership Committee of International Association for the Study of Lung Cancer (2012-2014). Dr. Li obtained her MD degree from Peking University Health Science Center (formerly Beijing Medical University) in China in 1989 and PhD in Molecular Immunology from Loyola University, Chicago, Illinois in 1996. She pursued resident training in Internal Medicine at the Beth Israel Medical Center and a Hematology/Oncology fellowship at Montefiore Medical Center, Albert Einstein College of Medicine in the Bronx, New York. She was subsequently recruited there as a faculty member until she moved to her current position at University of California at Davis in 2009. She is Board Certified in Internal Medicine, Hematology, and Medical Oncology.
Dr. Li is one of the founding members and a life-time member of the Chinese American Hematologists and Oncologists Network (CAHON). She been involved in many aspects that relate to CAHON’s twin primary missions: 1) to foster communications among Chinese American medical professionals for the delivery of high-quality health care to patients with neoplastic and hematological diseases, and 2) to promote medical information exchange between the United States and China in the field of Hematology and Oncology. She currently serves as the Director of Membership Committee and an executive committee member of CAHON. She represented CAHON to participate in a joint symposium on drug development at the 14th Chinese Society of Clinical Oncology (CSCO) annual meeting in Xiamen, China in September 2011. She is also a member of the Dean’s Great China Committee at UC Davis, School of Medicine. She has been actively engaged in curriculum development and teaching for exchange medical students and visiting physicians from China.